A Newspaper for the health conscious

Granules India’s declares third interim dividend

1 1 1 1 1 1 1 1 1 1 Rating 5.00 (1 Vote)

 DTMT Network
Revenue growth of 14% in the quarter ending December 2017 was the outcome of investments in capacity expansion in both APIs and PFIs, stated A P Chigurupati, CMD of Granules India Ltd.

Granules India Ltd. a pharmaceutical manufacturing company, has announced financial results for the quarter ended December 31, 2017.

Granules said in a press release that its standalone sales during the quarter were INR 413 Cr. In this quarter the company recorded EBITDA (Earnings before interest, taxes, depreciation, and amortization) and PAT (Profit After Tax) of INR 78 Cr. and INR 34 Cr. respectively.

The company's Board has approved third interim dividend of 25 paise per share of face value of Rs. 1 each.

"Our journey towards sustainability continues as we report steady growth in our business performance. Revenue growth of 14% in the current quarter is the outcome of our investments in capacity expansion in both APIs and PFIs,”  informed Mr. Krishna Prasad Chigurupati, Chairman & Managing Director.

The CMD added, “However, increased cost for some of our key raw materials and forex fluctuation has impacted profit for the quarter under review. Going ahead, we are optimistic of strengthening our growth by leveraging enhanced production capacities, until our new business initiatives start contributing positively as supplementary growth drivers of the Company.”

Leave your comments



  • No comments found


  • No comments found

GLS Pharma


Cubit Pharma

Medical Devices ASEAN 2018